BHB-1893 / Jiangsu Hengrui Pharma, Braveheart Bio - LARVOL DELTA

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants (clinicaltrials.gov) - P1 | N=58 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular

HRS/BHB-1893, a Next-Generation Cardiac Myosin Inhibitor, Improves Indices of Diastolic Function in Non-Obstructive Hypertrophic Cardiomyopathy: Evidence from in vitro Studies and Patients (AHA 2026) - "Abstract is embargoed at this time."

Preclinical • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P3 | N=228 | Active, not recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P2 | N=84 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Trial completion date: Aug 2025 ➔ Nov 2025 | Trial primary completion date: Aug 2025 ➔ Nov 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants (clinicaltrials.gov) - P1 | N=58 | Active, not recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiomyopathy • Cardiovascular

LIONHEART-HCM: BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P3 | N=210 | Not yet recruiting | Sponsor: Braveheart Bio, Inc.

New P3 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | N=36 ➔ 58

Enrollment change • Cardiomyopathy • Cardiovascular

Human Mass Balance Study of [¹⁴C]HRS-1893 (clinicaltrials.gov) - P1 | N=6 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Cardiomyopathy

Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS-1893, a cardiac myosin inhibitor, in healthy subjects. (PubMed, Br J Clin Pharmacol) - P1 | "HRS-1893 demonstrated favourable safety and PK profiles, with potential therapeutic efficacy among healthy subjects."

First-in-human • Journal • PK/PD data

BHB/HRS-1893 in non-obstructive hypertrophic cardiomyopathy (HEART FAILURE 2026) - No abstract available

Late-breaking abstract • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2025 ➔ Mar 2026

Enrollment open • Trial initiation date • Cardiovascular • Congestive Heart Failure • Heart Failure

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular

A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=38 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Cardiomyopathy • Cardiovascular

Efficacy And Safety Of BHB/HRS-1893 In Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From A 12-week Phase 2 Study (ACC 2026) - "Abstract is embargoed at this time."

Clinical • Late-breaking abstract • P2 data • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular

A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=38 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Cardiomyopathy • Cardiovascular

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

A Trial of HRS-1893 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Atridia Pty Ltd. | Recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Nephrology • Renal Disease

A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug (South China Morning Post) - "The deal gives Braveheart Bio exclusive worldwide rights to develop, manufacture and commercialise the drug...HRS-1893...outside mainland China, Hong Kong, Macau and Taiwan. Jiangsu Hengrui will receive an initial payment totalling US$75 million, which includes cash, Braveheart Bio shares and a near-term milestone payment of up to US$10 million."

Licensing / partnership • Obstructive Hypertrophic Cardiomyopathy

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1893 in patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, placebo-controlled phase 1 trial (ESC-WCC 2025) - "Conclusion HRS-1893 demonstrated favourable safety and PK profiles. It rapidly and effectively reduced resting and Valsalva LVOT-G, while keeping LVEF within the safety limits, providing a novel treatment option for patients with obstruction HCM."

Clinical • P1 data • PK/PD data • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P3 | N=216 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Trial of HRS-1893 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Atridia Pty Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy